Exhaustive Clinical Notes: Statin Management, Patient History, and Academic Pathway

Patient Case Evaluation: Statin Therapy and Lipid Management

• Patient Identification and Initial Statin Switch:

  • Patient Ilien was previously switched to moderate-intensity pravastatin due to reported side effects and complaints with prior statin therapy.
  • The primary side effect reported by the patient was statin-induced blood glucose elevation.

• Lipid Panel Verification and Rosuvastatin Pickup Timeline:

  • The patient was scheduled to complete a lipid panel laboratory test earlier in the week.
  • On September 1, the patient picked up a prescription for rosuvastatin.
  • Clinical instructions specified that the patient must not start taking rosuvastatin until after completing the lipid panel.
  • A chart check confirmed the lipid panel was not drawn at the start of the week, but was subsequently completed $2\,\text{days}$ prior.

• Efficacy, Statin Intensity, and Regimen Strategy:

  • Pravastatin demonstrated inadequate lipid-lowering efficacy and is categorized as a moderate-intensity statin.
  • The patient requires a high-intensity statin regimen (such as rosuvastatin or atorvastatin) to achieve necessary lipid goals.
  • The patient takes statin medications at nighttime.

• Statin-Induced Hyperglycemia Profile:

  • The patient expressed strong hesitation regarding non-pravastatin statins due to observed blood glucose elevation.
  • The patient recorded a fasting blood glucose increase of approximately $30\,\text{points}$ without food intake, attributed directly to statin administration.
  • Chart review is required to evaluate the precise magnitude of glucose rise relative to cardiovascular risk reduction benefits.

• Upcoming Provider Consultation:

  • The patient is scheduled to consult with Dr. Catapano on September 11th.
  • It is anticipated that Dr. Catapano will instruct the patient to resume atorvastatin or initiate rosuvastatin due to significant lipid level increases on pravastatin.

Academic and Professional Pathways in Pharmacy

• International Educational Progression (Bangladesh):

  • Undergraduate education was initiated in Bangladesh, completing $2\,\text{years}$ of study.
  • Enrollment in Bangladesh was in a Bachelor's in Pharmaceutical Science program, as PharmD (Doctor of Pharmacy) degrees are not offered in Bangladesh.

• Transition to the United States Educational System:

  • Relocated to North Carolina and completed undergraduate requirements at a local community college.
  • Direct undergraduate Bachelor's degrees in Pharmaceutical Science are not structured as standalone tracks in the U.S. higher education system in the same format, necessitating entry into a PharmD program.

• Subject Preferences and Career Goals:

  • Expressed strong affinity for chemistry (specifically organic chemistry), biology, pharmacy, and general healthcare.
  • Explicit preference for healthcare and pharmacy without any desire to become a Medical Doctor (MD).
  • Most rigorous and difficult prerequisite coursework was completed in the preceding academic year; current coursework consists of a final couple of remaining classes prior to walking/graduation.

Clinical Documentation, Electronic Chart Review, and Laboratory Metrics

• Documentation Gaps and Communication Logging:

  • Direct patient telephone calls received while commuting/running home were not consistently entered into the electronic medical record (EMR).
  • A complete gap in documented clinical visits exists between April and August.

• EMR Data Retrieval Locations:

  • Standard laboratory values (such as International Normalized Ratio / INR) are retrieved in the EMR by directly querying "INR".
  • Home monitoring records and data logs are archived under the "media" tab within the electronic chart.

• Laboratory Timeline and Metrics:

  • Chart review revealed recorded metric points including $65$, $31619301$, $71036$, and $72925$.
  • No laboratory monitoring or testing was recorded during the month of May.
  • The patient was the initial participant who started home monitoring and subsequently identified that home INR monitors were inaccurate.

• Concurrent Pharmacotherapy Evaluation:

  • Evaluation of concomitant allopurinol ("Allepipanal") therapy alongside lipid panel optimization.

Cardiovascular Surgical History and Clinical Risk Factors

• Surgical Procedures and Timeline:

  • The patient underwent cardiac valve replacement surgery in March or April.
  • In addition to valve replacement, the surgical intervention required $3\text{ coronary artery bypasses}$ (CABG).

• Cardiovascular Risk Profile and Comorbidities:

  • Chronological age is relatively young given the extent of surgical interventions.
  • Co-existing medical diagnosis of diabetes mellitus.
  • Co-existing diagnosis of elevated blood pressure / hypertension.
  • Absence of history of cerebrovascular accident (CVA / stroke).

Questions & Discussion

• Attendance and Session Logistics:
  • Miss Camilla noted needing to leave early and returning shortly.
  • Inquiry regarding whether Mr. Miller attended or missed the session, with the conclusion that he likely forgot or was absent.
  • Inquiry regarding whether dosage adjustments were executed during the preceding visit.